The Max Foundation Creates Subsidiary Organization, MaxAid, to Further Mission

Now in its 20th year, The Max Foundation is undergoing exciting strategic changes aimed at strengthening organizational efforts to improve global access to cancer treatment, care and support. To that end, we announce the launch of MaxAid, a subsidiary organization set up by The Max Foundation to further its mission. MaxAid is a Washington nonprofit corporation with its own IRS determination letter of 501(c)(3) public charity status.

From its launch, MaxAid will host our collaboration with Novartis, a leading global healthcare company, around humanitarian access to their medicines Glivec® and Tasigna® in a joint initiative. In the future similar contributions from other partnering companies may also be received by MaxAid.

“The advent of MaxAid is exciting for The Max Foundation because it enables us to take our operational work to the next level,” says Paula Boultbee, Chair of the Board for The Max Foundation.  She continues, “By launching MaxAid, we accomplish yet another strategic milestone for The Max Foundation in our role as a bridge to access for people facing cancer currently without treatment in lower resource settings around the world.”

This positive step of launching MaxAid in 2017 promises to keep us well positioned to decrease avoidable cancer deaths in the least developed countries and help people around the world to face cancer with dignity and hope.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Partners with Leading Pharmaceutical Company to Advance Health Equity Through Expanded CML Treatment Access for Patients in 36 Low-Middle-Income Countries

    Availability of Novartis Scemblix® (asciminib) starting in 2023 helps ensure people living with later lines of CML in low-income countries have access to the latest innovation SEATTLE – Dec. 12, 2022 – The Max Foundation (Max), a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally,….

  • It was heartwarming looking at my son Max’s picture at the Patan Hospital: Pat Garcia-Gonzalez

    It was heartwarming looking at my son Max’s picture at the Patan Hospital: Pat Garcia-Gonzalez

    Read the interview with the Nepal Live Today – October 21, 2024.

  • The Max Foundation expands collaboration with Pfizer

    The Max Foundation expands collaboration with Pfizer

    The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.